Cargando…
The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study
AIM: Chronic diseases often occur simultaneously and tend to be associated with adverse health outcomes, but limited research has been undertaken to understand their role in lung cancer mortality. Therefore, this study aims to describe the prevalence and patterns of having one (comorbidity) or ≥ 2 c...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461961/ https://www.ncbi.nlm.nih.gov/pubmed/34556072 http://dx.doi.org/10.1186/s12885-021-08801-9 |
_version_ | 1784572098458419200 |
---|---|
author | Niksic, Maja Redondo-Sanchez, Daniel Chang, Yoe-Ling Rodriguez-Barranco, Miguel Exposito-Hernandez, Jose Marcos-Gragera, Rafael Oliva-Poch, Ester Bosch-Barrera, Joaquim Sanchez, Maria-Jose Luque-Fernandez, Miguel Angel |
author_facet | Niksic, Maja Redondo-Sanchez, Daniel Chang, Yoe-Ling Rodriguez-Barranco, Miguel Exposito-Hernandez, Jose Marcos-Gragera, Rafael Oliva-Poch, Ester Bosch-Barrera, Joaquim Sanchez, Maria-Jose Luque-Fernandez, Miguel Angel |
author_sort | Niksic, Maja |
collection | PubMed |
description | AIM: Chronic diseases often occur simultaneously and tend to be associated with adverse health outcomes, but limited research has been undertaken to understand their role in lung cancer mortality. Therefore, this study aims to describe the prevalence and patterns of having one (comorbidity) or ≥ 2 chronic diseases (multimorbidity) among lung cancer patients in Spain, and to examine the association between comorbidity or multimorbidity and short-term mortality risk at six months after cancer diagnosis. METHODS: In this population-based cohort study, data were drawn from two Spanish population-based cancer registries, Girona and Granada, and electronic health records. We identified 1259 adult lung cancer patients, diagnosed from 1st January 2011 to 31st December 2012. We identified the most common patterns of individual comorbidities and their pairwise correlations. We used a flexible parametric modelling approach to assess the overall short-term mortality risk 6 months after cancer diagnosis by levels of comorbidity after adjusting for age, sex, smoking status, province of residence, surgery, cancer stage, histology, and body mass index. RESULTS: We found high prevalence of comorbidity in lung cancer patients, especially among the elderly, men, those diagnosed with advanced-stage tumours, smokers, and obese patients. The most frequent comorbidities were chronic obstructive pulmonary disease (36.6%), diabetes (20.7%) and heart failure (16.8%). The strongest pairwise correlation was the combination of heart failure with renal disease (r = 0.20, p < 0.01), and heart failure with diabetes (r = 0.16, p < 0.01). Patients with either one or two or more comorbidities had 40% higher overall mortality risk than those without comorbidities (aHR for comorbidity: 1.4, 95%CI: 1.1–1.7; aHR for multimorbidity: 1.4, 95%CI: 1.1–1.8), when relevant confounding factors were considered. CONCLUSIONS: The presence of comorbid diseases, rather than the number of comorbidities, was associated with increasing the risk of short-term lung cancer mortality in Spain. Comorbidity was a consistent and independent predictor of mortality among lung cancer patients, six months after diagnosis. The most common comorbid conditions were age-, obesity- and tobacco-related diseases. Our findings highlight the need to develop targeted preventive interventions and more personalised clinical guidelines to address the needs of lung cancer patients with one or more comorbidities in Spain. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08801-9. |
format | Online Article Text |
id | pubmed-8461961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84619612021-09-24 The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study Niksic, Maja Redondo-Sanchez, Daniel Chang, Yoe-Ling Rodriguez-Barranco, Miguel Exposito-Hernandez, Jose Marcos-Gragera, Rafael Oliva-Poch, Ester Bosch-Barrera, Joaquim Sanchez, Maria-Jose Luque-Fernandez, Miguel Angel BMC Cancer Research AIM: Chronic diseases often occur simultaneously and tend to be associated with adverse health outcomes, but limited research has been undertaken to understand their role in lung cancer mortality. Therefore, this study aims to describe the prevalence and patterns of having one (comorbidity) or ≥ 2 chronic diseases (multimorbidity) among lung cancer patients in Spain, and to examine the association between comorbidity or multimorbidity and short-term mortality risk at six months after cancer diagnosis. METHODS: In this population-based cohort study, data were drawn from two Spanish population-based cancer registries, Girona and Granada, and electronic health records. We identified 1259 adult lung cancer patients, diagnosed from 1st January 2011 to 31st December 2012. We identified the most common patterns of individual comorbidities and their pairwise correlations. We used a flexible parametric modelling approach to assess the overall short-term mortality risk 6 months after cancer diagnosis by levels of comorbidity after adjusting for age, sex, smoking status, province of residence, surgery, cancer stage, histology, and body mass index. RESULTS: We found high prevalence of comorbidity in lung cancer patients, especially among the elderly, men, those diagnosed with advanced-stage tumours, smokers, and obese patients. The most frequent comorbidities were chronic obstructive pulmonary disease (36.6%), diabetes (20.7%) and heart failure (16.8%). The strongest pairwise correlation was the combination of heart failure with renal disease (r = 0.20, p < 0.01), and heart failure with diabetes (r = 0.16, p < 0.01). Patients with either one or two or more comorbidities had 40% higher overall mortality risk than those without comorbidities (aHR for comorbidity: 1.4, 95%CI: 1.1–1.7; aHR for multimorbidity: 1.4, 95%CI: 1.1–1.8), when relevant confounding factors were considered. CONCLUSIONS: The presence of comorbid diseases, rather than the number of comorbidities, was associated with increasing the risk of short-term lung cancer mortality in Spain. Comorbidity was a consistent and independent predictor of mortality among lung cancer patients, six months after diagnosis. The most common comorbid conditions were age-, obesity- and tobacco-related diseases. Our findings highlight the need to develop targeted preventive interventions and more personalised clinical guidelines to address the needs of lung cancer patients with one or more comorbidities in Spain. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08801-9. BioMed Central 2021-09-24 /pmc/articles/PMC8461961/ /pubmed/34556072 http://dx.doi.org/10.1186/s12885-021-08801-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Niksic, Maja Redondo-Sanchez, Daniel Chang, Yoe-Ling Rodriguez-Barranco, Miguel Exposito-Hernandez, Jose Marcos-Gragera, Rafael Oliva-Poch, Ester Bosch-Barrera, Joaquim Sanchez, Maria-Jose Luque-Fernandez, Miguel Angel The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study |
title | The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study |
title_full | The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study |
title_fullStr | The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study |
title_full_unstemmed | The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study |
title_short | The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study |
title_sort | role of multimorbidity in short-term mortality of lung cancer patients in spain: a population-based cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461961/ https://www.ncbi.nlm.nih.gov/pubmed/34556072 http://dx.doi.org/10.1186/s12885-021-08801-9 |
work_keys_str_mv | AT niksicmaja theroleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT redondosanchezdaniel theroleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT changyoeling theroleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT rodriguezbarrancomiguel theroleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT expositohernandezjose theroleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT marcosgragerarafael theroleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT olivapochester theroleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT boschbarrerajoaquim theroleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT sanchezmariajose theroleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT luquefernandezmiguelangel theroleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT niksicmaja roleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT redondosanchezdaniel roleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT changyoeling roleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT rodriguezbarrancomiguel roleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT expositohernandezjose roleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT marcosgragerarafael roleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT olivapochester roleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT boschbarrerajoaquim roleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT sanchezmariajose roleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy AT luquefernandezmiguelangel roleofmultimorbidityinshorttermmortalityoflungcancerpatientsinspainapopulationbasedcohortstudy |